+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rytary

  • ID: 4775093
  • Report
  • June 2018
  • Region: Global
  • 14 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component. Rytary is dosed three times daily, although its pharmacokinetic profile allows for smoother levodopa levels and consequently fewer motor fluctuations than conventional, immediate-release carbidopa + levodopa.

Rytary was finally approved by the US Food and Drug Administration in January 2015, despite over three years of regulatory scrutiny. Impax’s first submission in December 2011 resulted in a complete response letter requiring a re-inspection of its manufacturing facility. In the meantime, Impax’s former development partner GlaxoSmithKline terminated their agreement, leaving Impax to conclude the regulatory process and commercialize the product by itself.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Rytary : Parkinson's disease

LIST OF FIGURES
Figure 1: Rytary for Parkinson’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of Rytary for Parkinson’s disease
Figure 3: The authors drug assessment summary of Rytary for Parkinson’s disease
Figure 4: Rytary sales for Parkinson’s disease in the US, 2016–25

LIST OF TABLES
Table 1: Rytary drug profile
Table 2: Rytary pivotal trial data in Parkinson’s disease
Table 3: Rytary sales for Parkinson’s disease in the US ($m), 2016–25
Note: Product cover images may vary from those shown
Adroll
adroll